Pharmareferent Rx
About the job
- Several years of field-sales experience with prescription medicines (Rx).
- Qualification as a pharmaceutical representative under § 75 of the German Medicines Act (AMG).
- Sound knowledge of pharmacology and a strong understanding of scientific studies and medical contexts.
- Strong sales ability and capacity to persuade and support customers sustainably.
- Ability to communicate complex scientific content clearly.
- Ability to work independently, in a structured manner, and toward objectives.
- Teamwork skills and strong digital affinity.
- Valid Class B driver's license.
- Willingness to travel extensively within the sales territory.
- Residence within the territory or nearby.
- Plan, prepare, and conduct indication-related professional discussions about Rx products.
- Manage the sales territory strategically, including revenue, activity, and potential planning.
- Analyze market, competitor, and territory data to derive effective sales measures.
- Build, maintain, and develop lasting customer relationships and regional networks.
- Develop and implement regional sales strategies in close collaboration with Marketing, Medical Affairs, and regional leadership.
- Organize and conduct training, continuing education, and regional events for medical professionals.
- Document activities and medicine sample distribution fully and compliantly in the Veeva CRM system.
- Ensure compliance with all relevant legal and compliance requirements.
- Continuously update knowledge of products, therapy areas, and current scientific findings.
- Contribute to projects and support digital sales activities.
- Handle administrative tasks such as expense reports and reporting.
- Cover vacancies in neighboring territories when needed.
- Report adverse drug reactions on time in accordance with applicable pharmacovigilance requirements.
About the company
Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.
Company Size
10,001+
Company Stage
IPO
Headquarters
Canonsburg, Pennsylvania
Founded
1961
Get referred to Viatris
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose 5% to $3.8 billion, and guidance increased.
- Debt fell after $900 million repayment, reducing gross leverage to 2.9x.
- Tyrvaya divestiture, Gwyn Lo, and meloxicam NDA support a higher-value portfolio shift.
What critics are saying
- Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100-$150 million.
- Greater China procurement changes pressure hospital volumes, squeezing one of Viatris's fastest growth engines.
- Generic pricing MDL and ongoing patent fights in Japan keep legal overhangs persistent.
What makes Viatris unique
- Viatris pairs 165-country reach with complex generics, branded drugs, and biosimilars.
- Japan approved WAKIX on September 16, 2026, expanding first-in-class sleep medicine reach.
- FDA approved Gwyn Lo on July 29, 2026, adding a differentiated women’s health product.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Life Insurance
- 401(k) Retirement Plan
- 401(k) Company Match
- Wellness Program
- Paid Holidays